Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Topiramate | Topamax | 4.4. Special warnings and precautions for use | Kidney Stones | Oct,2022 |
| Dolutegravir, Lamivudine | Dovato | 4.8. Undesirable effects | Creatinine phosphokinase elevation | Oct,2022 |
| Lansoprazole | Lanzor | 4.4. Special warnings and precautions for use | Acute tubulointerstitial nephritis | Oct,2022 |
| Dexlansoprazole | Dexilant | 5.2 Pharmacokinetic properties | Effect of CYP2C19 Polymorphism on Systemic Exposure of Dexlansoprazole | Jul, 2024 |
| Dexketoprofen | Ketesse | 4.6. Fertility, pregnancy and lactation | Cause oligohydramnios resulting from foetal renal dysfunction | Oct,2022 |
| Ciclosporin | Invokana | 4.5 Interaction with other medicinal products and other forms of interaction | "Lithium " | Jan,2024 |